165 related articles for article (PubMed ID: 26866698)
1. A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
Saba C; Paoloni M; Mazcko C; Kisseberth W; Burton JH; Smith A; Wilson-Robles H; Allstadt S; Vail D; Henry C; Lana S; Ehrhart EJ; Charles B; Kent M; Lawrence J; Burgess K; Borgatti A; Suter S; Woods P; Gordon I; Vrignaud P; Khanna C; LeBlanc AK
PLoS One; 2016; 11(2):e0149194. PubMed ID: 26866698
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Blakeley JO; Grossman SA; Mikkelsen T; Rosenfeld MR; Peereboom D; Nabors LB; Chi AS; Emmons G; Garcia Ribas I; Supko JG; Desideri S; Ye X
J Neurooncol; 2015 Oct; 125(1):123-31. PubMed ID: 26285766
[TBL] [Abstract][Full Text] [Related]
3. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.
Liang H; Tan AR
IDrugs; 2010 Sep; 13(9):646-56. PubMed ID: 20799148
[TBL] [Abstract][Full Text] [Related]
4. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
6. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
8. Appraising iniparib, the PARP inhibitor that never was--what must we learn?
Mateo J; Ong M; Tan DS; Gonzalez MA; de Bono JS
Nat Rev Clin Oncol; 2013 Dec; 10(12):688-96. PubMed ID: 24129347
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
[TBL] [Abstract][Full Text] [Related]
10. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
Allstadt Frazier S; McKemie DS; Guerrero TA; LaChapelle H; Skorupski KA; Kass PH; Rodriguez CO
Vet Comp Oncol; 2014 Mar; 12(1):1-9. PubMed ID: 22364238
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Bell-McGuinn KM; Konner JA; Tew WP; Hensley ML; Iasonos A; Charpentier E; Mironov S; Sabbatini P; Aghajanian C
Int J Gynecol Cancer; 2016 Feb; 26(2):255-60. PubMed ID: 26745694
[TBL] [Abstract][Full Text] [Related]
13. Iniparib in metastatic triple-negative breast cancer.
Domagala P; Lubinski J; Domagala W
N Engl J Med; 2011 May; 364(18):1780; author reply 1781. PubMed ID: 21542760
[No Abstract] [Full Text] [Related]
14. A review of iniparib in ovarian cancer.
Wilkinson-Ryan I; Mutch D
Expert Opin Investig Drugs; 2013 Mar; 22(3):399-405. PubMed ID: 23394483
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study
Athanasiadi I; Geigy C; Hilger RA; Meier V; Rohrer Bley C
Vet Comp Oncol; 2017 Mar; 15(1):94-104. PubMed ID: 25689225
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
